News Releases

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...

Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation...

Partner CSPC Pharmaceutical Group Limited's ongoing Phase 1 SYSA1801 (EO-3021) clinical trial data selected for poster presentation and poster discussion at ASCO 2023 Presented EO-3021 preclinical...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...

EO-3021 demonstrated anti-tumor activity in preclinical models expressing varying levels of Claudin 18.2 EO-3021 induced a confirmed partial response in a patient with metastatic gastric cancer...

- Company plans to highlight preclinical proof-of-concept data for EO-3021 in an oral presentation at the New Drugs on the Horizon special session NEW YORK, March 14, 2023 /PRNewswire/ --...

Remain on track to present EO-3021 preclinical proof-of-concept data in first half of 2023, and initiate Phase 1 clinical trial in the US in second half of 2023 Announced pipeline prioritization...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with...

Prioritizing the development of EO-3021, a potential best-in-class ADC targeting Claudin18.2, and additional pipeline programs including those through its existing partnership with Caris Life Sciences

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...

On track to report additional interim seribantumab data from the Phase 2 CRESTONE study in the first half of 2023 Preparations are underway to initiate a Phase 1 clinical trial of EO-3021 in the...

Presented initial seribantumab proof-of-concept data from Phase 2 CRESTONE study at ASCO 2022, including 33% response rate with two complete responses across all tumor types harboring NRG1 fusions...

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...

Initial tranche supports the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and execution of Company's pipeline NEW YORK, July 28, 2022...

Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801) Expands pipeline to now include two clinical stage precision oncology candidates for...

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...

Positive initial data support the potential of seribantumab to induce deep and durable benefit for patients with tumors harboring NRG1 fusions Clinical activity observed includes a 33% response...

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...

Initial seribantumab clinical data from Phase 2 CRESTONE study selected for oral presentation at ASCO 2022 David Dornan, PhD appointed Chief Scientific Officer, bringing deep oncology R&D and drug...

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...